Zuzana Motovska et al. JACC 2018;71:

Slides:

Advertisements

Similar presentations

Valsartan Antihypertensive Long-Term Use Evaluation Results

Advertisements

Trial profile Fox K et al. Lancet 2008;372:

Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

GP Prescribing Behaviour Change Calcium Supplement Prescribing Cessation Kenneth Chin.

Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Discontinuation of medication after nonfatal event: MI

The SPRINT Research Group

From: Risks of Cardiovascular Adverse Events and Death in Patients with Previous Stroke Undergoing Emergency Noncardiac, Nonintracranial Surgery:The Importance.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

Antiplatelet Therapy and Secondary Prevention

Robert W. Yeh et al. JACC 2017;70:

Bjarne L. Nørgaard et al. JACC 2018;72:

Preventive Angioplasty in Myocardial Infarction Trial

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Potential mechanisms whereby statins may reduce the risk of stroke

Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different.

Elements of Vietnam’s HIV/AIDS patient monitoring system as of 31 December 2016 (adapted from 2016 National HIV/AIDS Report10). ART, antiretroviral therapy;

47% 50% 21% Event Rate 35 p= # Pts 20 Death 15

Berger JS, et al. JAMA 2009;301:

Flow Diagram of the Trial Selection Process

Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.

Behnam N. Tehrani et al. JACC 2019;73:

Collet JP, et al. Lancet 2009;373:309-17

European Heart Journal Advance Access

Baseline Characteristics of the Patients – Part I

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Comparison of Baseline Characteristics by Primary End Point

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Pamela E. Scott et al. JACC 2018;71:

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Javier Escaned et al. JCIN 2018;11:

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Comparison of investigator-reported and mortality adjudication committee-adjudicated fatal events (myocardial infarction, sudden death, sudden cardiac.

Presentation transcript:

Zuzana Motovska et al. JACC 2018;71:371-381 Study Flow Chart Occurrences of events during the study follow-up were recorded at the time of scheduled visits. After the study, the occurrence of monitored events was further verified by connecting the study’s electronic database with data from the national databases of the Institute of Health Information and Statistics of the Czech Republic. No patients were lost to follow-up. Information about the precise date of switching from the study medication was not specified in 3 patients; in these patients, the date of the visit during which the termination of therapy was recorded was used as the treatment discontinuation date. *The combined efficacy endpoint was cardiovascular death, nonfatal myocardial infarction, or stroke. Missing information in 19 patients was supplemented from national registries of the Institute of Health Information and Statistics of the Czech Republic. †For missing end-of-treatment data in 3 patients, a visit date was added corresponding to the date that treatment discontinuation was reported. EP = efficacy endpoint; FU = follow-up; PRAGUE-18 = Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction. Zuzana Motovska et al. JACC 2018;71:371-381 2018 The Authors